Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations

Inclusion Criteria:

* Written informed consent provided.
* Males or females aged ≥18 years.
* Chest CT, brain CT or MRI, ECT, abdominal and double-neck B-, or whole body PET-CT examination in 4 weeks before complete resection.
* Pathological diagnosed of non-small cell lung cancer.
* Diagnosed as stage IIIA.
* In 4 weeks after complete resection pts start to accept the adjuvant therapy in this study, previously did not receive any anti-tumor therapy.
* EGFR activating mutation in exon 19 or 21 and KARS
* ECOG performance status 0-1.
* Life expectancy ≥3 months.
* Adequate hematological function:Absolute neutrophil count (ANC) ≥1.5 x 109/L, and Platelet count ≥100 x 109/L, and Hemoglobin ≥9 g/dL (may be transfused to maintain or exceed this level).
* Adequate liver function: Total bilirubin ≤ 1.5 x upper limit of normal (ULN);Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 x ULN.
* Adequate renal function:Serum creatinine ≤ 1.25 x ULN, and creatinine clearance ≥ 60 ml/min.
* Able to comply with the required protocol and follow-up procedures, and able to receive oral medications.
* Patients must be nonpregnant and non-lactating.Patients of childbearing potential must implement an effective method of contraception during the study. All female Patients, except those who are postmenopausal or surgically sterilized, must have a negative pre-study serum or urine pregnancy test. .

Exclusion Criteria:

* Patients with prior exposure to agents directed at the HER axis (e.g. erlotinib, gefitinib, cetuximab, trastuzumab).
* Patients with prior chemotherapy or therapy with systemic anti-tumour therapy.
* Patients with prior radiotherapy.
* History of another malignancy in the last 5 years with the exception of the following:Cured basal cell carcinoma of the skin and cured in situ carcinoma of the uterine cervix are permitted.
* Any evidence confirmed tumor recurrence before adjuvant treatment.
* Any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease).
* Any evidence of clinically active interstitial lung disease.
* Eye inflammation or eye infection not fully treated or conditions predisposing the subject to this.
* Known human immunodeficiency virus (HIV) infection.
* Known hypersensitivity to Tarceva or NVB or cisplatin.
* Pregnancy or breast-feeding women.
* ECOG performance status ≥ 2.
* Ingredients mixed with small cell lung cancer patients
* Evidence of any other disease, neurological or metabolic dysfunction, physical examination or laboratory finding giving reasonable suspicion of a disease or condition that contraindicated the use of an investigational drug or puts the subject at high risk for treatment-related complications.